Guru Fundamental Report for MSFT

Validea's guru fundamental report indicates that Microsoft (MSFT) receives an 86% rating based on their Patient Investor model, which is derived from Warren Buffett's investment strategy focused on firms with predictable profitability, low debt, and reasonable valuations; a score above 80% indicates interest, while a score above 90% indicates strong interest. MSFT passes key criteria such as earnings predictability, debt service, return on equity, and free cash flow, but fails the initial rate of return test.

Analysis

Microsoft Corp (MSFT), a large-cap growth stock within the Software & Programming sector, has garnered an 86% rating from Validea's Patient Investor model, which is structured on Warren Buffett's investment principles emphasizing long-term, predictable profitability, low debt, and reasonable valuations. This score surpasses the 80% threshold, indicating a notable level of interest from this specific strategic model. The assessment highlights MSFT's strengths by confirming it passes crucial tests such as Earnings Predictability, Debt Service, Return on Equity, Return on Total Capital, Free Cash Flow, Use of Retained Earnings, and Share Repurchase. However, the report also specifies that MSFT fails the 'Initial Rate of Return' criterion, suggesting that while fundamentally sound, its current market valuation might not offer a sufficiently attractive immediate return according to this particular metric within the model.

Key Decisions for Investors

• Investors aligned with long-term, fundamentally-driven strategies should note MSFT's favorable 86% rating under Validea's Buffett-style model, supported by strong earnings predictability, debt management, and free cash flow.
• Carefully assess MSFT's current valuation, as its failure on the 'Initial Rate of Return' criterion suggests the present stock price might not meet the model's threshold for immediate return expectations, despite robust fundamentals.
• For those considering new positions, weigh the company's demonstrated strengths in profitability and capital returns against the valuation concern flagged by the Patient Investor model's 'Initial Rate of Return' test.